|
1
|
Gucalp A and Traina TA: Triple-negative
breast cancer: Role of the androgen receptor. Cancer J. 16:62–65.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Gucalp A, Tolaney S, Isakoff SJ, Ingle JN,
Liu MC, Carey LA, Blackwell K, Rugo H, Nabell L, Forero A, et al:
Phase II trial of bicalutamide in patients with androgen
receptor-positive, estrogen receptor-negative metastatic Breast
Cancer. Clin Cancer Res. 19:5505–5512. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Baniahmad A: Nuclear hormone receptor
co-repressors. J Steroid Biochem Mol Biol. 93:89–97. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Dehm SM and Tindall DJ: Molecular
regulation of androgen action in prostate cancer. J Cell Biochem.
99:333–344. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Díaz-Chico Nicolás B, Rodríguez Germán F,
González A, Ramírez R, Bilbao C, de León Cabrera A, Jaime Aguirre
A, Chirino R, Navarro D and Díaz-Chico JC: Androgens and androgen
receptors in breast cancer. J Steroid Biochem Mol Biol. 105:1–15.
2007. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Jovanovic M and Hengartner MO: miRNAs and
apoptosis: RNAs to die for. Oncogene. 25:6176–6187. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Bussing I, Slack FJ and Grosshans H: let-7
microRNAs in development, stem cells and cancer. Trends Mol Med.
14:400–409. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Schickel R, Boyerinas B, Park SM and Peter
ME: MicroRNAs: Key players in the immune system, differentiation,
tumorigenesis and cell death. Oncogene. 27:5959–5974. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Stefani G and Slack FJ: Small non-coding
RNAs in animal development. Nat Rev Mol Cell Biol. 9:219–230. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Cho WC: OncomiRs: The discovery and
progress of microRNAs in cancers. Mol Cancer. 6:602007. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Shi XB, Tepper CG and deVere White RW:
Cancerous miRNAs and their regulation. Cell Cycle. 7:1529–1538.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Shi XB, Xue L, Yang J, Ma AH, Zhao J, Xu
M, Tepper CG, Evans CP, Kung HJ and deVere White RW: An
androgen-regulated miRNA suppresses Bak1 expression and induces
androgen-independent growth of prostate cancer cells. Proc Natl
Acad Sci USA. 104:19983–19988. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Takayama K, Tsutsumi S, Katayama S,
Okayama T, Horie-Inoue K, Ikeda K, Urano T, Kawazu C, Hasegawa A,
Ikeo K, et al: Integration of cap analysis of gene expression and
chromatin immunoprecipitation analysis on array reveals genome-wide
androgen receptor signaling in prostate cancer cells. Oncogene.
30:619–630. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Lyu S, Yu Q, Ying G, Wang S, Wang Y, Zhang
J and Niu Y: Androgen receptor decreases CMYC and KRAS expression
by upregulating let-7a expression in ER-, PR-, AR+ breast cancer.
Int J Oncol. 44:229–237. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Epis MR, Giles KM, Barker A, Kendrick TS
and Leedman PJ: miR-331-3p regulates ERBB-2 expression and androgen
receptor signaling in prostate cancer. J Biol Chem.
284:24696–24704. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Hagman Z, Haflidadóttir BS, Ceder JA,
Larne O, Bjartell A, Lilja H, Edsjö A and Ceder Y: miR-205
negatively regulates the androgen receptor and is associated with
adverse outcome of prostate cancer patients. Br J Cancer.
108:1668–1676. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Shi XB, Xue L, Ma AH, Tepper CG,
Gandour-Edwards R, Kung HJ and deVere White RW: Tumor suppressive
miR-124 targets androgen receptor and inhibits proliferation of
prostate cancer cells. Oncogene. 32:4130–4138. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Yu Q, Niu Y, Liu N, Zhang JZ, Liu TJ,
Zhang RJ, Wang SL, Ding XM and Xiao XQ: Expression of androgen
receptor in breast cancer and its significance as a prognostic
factor. Ann Oncol. 22:1288–1294. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Hall RE, Birrell SN, Tilley WD and
Sutherland RL: MDA-MB-453, an androgen-responsive human breast
carcinoma cell line with high level androgen receptor expression.
Eur J Cancer. 30A:484–490. 1994. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Yeap BB, Krueger RG and Leedman PJ:
Differential posttranscriptional regulation of androgen receptor
gene expression by androgen in prostate and breast cancer cells.
Endocrinology. 140:3282–3291. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Vranic S, Gatalica Z and Wang ZY: Update
on the molecular profile of the MDA-MB-453 cell line as a model for
apocrine breast carcinoma studies. Oncol Lett. 2:1131–1137.
2011.PubMed/NCBI
|
|
22
|
Chen C, Ridzon DA, Broomer AJ, Zhou Z, Lee
DH, Nguyen JT, Barbisin M, Xu NL, Mahuvakar VR, Andersen MR, et al:
Real-time quantification of microRNAs by stem-loop RT-PCR. Nucleic
Acids Res. 33:e1792005. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Louie MC, Yang HQ, Ma AH, Xu W, Zou JX,
Kung HJ and Chen HW: Androgen-induced recruitment of RNA polymerase
II to a nuclear receptor-p160 coactivator complex. Proc Natl Acad
Sci USA. 100:2226–2230. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Seifer DB, MacLaughlin DT, Penzias AS,
Behrman HR, Asmundson L, Donahoe PK, Haning RV Jr and Flynn SD:
Gonadotropin-releasing hormone agonist-induced differences in
granulosa cell cycle kinetics are associated with alterations in
follicular fluid mullerian-inhibiting substance and androgen
content. J Clin Endocrinol Metab. 76:711–714. 1993. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Liu YN, Liu Y, Lee HJ, Hsu YH and Chen JH:
Activated androgen receptor downregulates E-cadherin gene
expression and promotes tumor metastasis. Mol Cell Biol.
28:7096–7108. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Cheng CW, Wang HW, Chang CW, Chu HW, Chen
CY, Yu JC, Chao JI, Liu HF, Ding SL and Shen CY: MicroRNA-30a
inhibits cell migration and invasion by downregulating vimentin
expression and is a potential prognostic marker in breast cancer.
Breast Cancer Res Treat. 134:1081–1093. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Feng J, Li L, Zhang N, Liu J, Zhang L, Gao
H, Wang G, Li Y, Zhang Y, Li X, et al: Androgen and AR contribute
to breast cancer development and metastasis: An insight of
mechanisms. Oncogene. 36:2775–2790. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Chang CW, Yu JC, Hsieh YH, Yao CC, Chao
JI, Chen PM, Hsieh HY, Hsiung CN, Chu HW, Shen CY and Cheng CW:
MicroRNA-30a increases tight junction protein expression to
suppress the epithelial-mesenchymal transition and metastasis by
targeting Slug in breast cancer. Oncotarget. 7:16462–16478. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Guo F, Chen H, Chang J and Zhang L:
Mutation R273H confers p53 a stimulating effect on the IGF-1R-AKT
pathway via miR-30a suppression in breast cancer. Biomed
Pharmacother. 78:335–341. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Fu J, Xu X, Kang L, Zhou L, Wang S, Lu J,
Cheng L, Fan Z, Yuan B, Tian P, et al: miR-30a suppresses breast
cancer cell proliferation and migration by targeting Eya2. Biochem
Biophys Res Commun. 445:314–319. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Xiong J, Wei B, Ye Q and Liu W:
MiR-30a-5p/UBE3C axis regulates breast cancer cell proliferation
and migration. Biochem Biophys Res Commun. 2016.(Epub ahead of
print). View Article : Google Scholar
|
